When looking at the study, Jensen said it is particularly “concerning” to see that abortion ban states saw a decline in use of mifepristone, which “reflects growing access disparities between restricted and non-restricted states, which could further widen existing disparities in maternal mortality and morbidity.”
Jensen added that patients are put at an increased risk of complications — such as infection or hemorrhage— when they aren’t presented with all options. These complications could require more invasive procedures, lengthy hospital stays or could even lead to death.
Read more at Salon